Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | TACR1 | P25103 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12552887 | 1.00 | TSHR (0.56) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL13108199 | 0.85 | TSHR (0.48) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL19992384 | 0.84 | KMT2A (0.58) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL12552888 | 0.84 | KMT2A (0.58) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL12552879 | 0.84 | KMT2A (0.58) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL18631435 | 0.84 | TSHR (0.52) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL21239569 | 0.83 | TSHR (0.56) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL14453899 | 0.83 | TSHR (0.61) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL2234953 | 0.83 | TSHR (0.61) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL22647527 | 0.82 | TSHR (0.50) | TSHRKMT2ACA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116670108-A | Ether compounds as volatiles for treating amino acid based substrates such as skin and hair | 迈图高新材料有限责任公司 | 2023-08-29 | — | — | CN | claimed |
| CN-116670108-A | Ether compounds as volatiles for treating amino acid based substrates such as skin and hair | 迈图高新材料有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-04-14 | — | — | US | disclosed |
| US-9120810-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BOARD INSTITUTE, INC. (US) | 2015-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | IDH1, IDH2, IDH3A | TSHR 3796/4885KMT2A 1147/4885CA1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.